Vir Biotechnology, Inc.

Direct answer

Vir Biotechnology, Inc. is publicly traded on NASDAQ under the ticker VIR.

Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at...

Can you invest in Vir Biotechnology, Inc.?

Yes. Vir Biotechnology, Inc. is publicly traded on NASDAQ under the ticker VIR.

View deeper analysis

View detailed research on MarketSnap, including financials, valuation tools, and analyst context.

Open research for Vir Biotechnology, Inc.

Detailed equity research is provided by MarketSnap.